22.50Open22.50Pre Close0 Volume0 Open Interest40.00Strike Price0.00Turnover741.90%IV-468.18%PremiumJan 17, 2025Expiry Date36.92Intrinsic Value100Multiplier22DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6967Delta0.0655Gamma0.08Leverage Ratio-0.0421Theta-0.0125Rho-0.06Eff Leverage0.0026Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet